NCT02873962 2026-04-01A Phase II Study Of Nivolumab/ Bevacizumab/RucaparibDana-Farber Cancer InstitutePhase 2 Active not recruiting72 enrolled 16 charts
NCT02711137 2025-10-21Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesIncyte CorporationPhase 1/2 Terminated137 enrolled 31 charts